(Q52641912)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Cancer immunotherapy using checkpoint blockade (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jedd D. Wolchok

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

2

Jedd D Wolchok

1 reference

http://europepmc.org/abstract/MED/29567705

5 May 2018

Antoni Ribas

series ordinal

1

object named as

Antoni Ribas

1 reference

http://europepmc.org/abstract/MED/29567705

5 May 2018

language of work or name

English

0 references

publication date

22 March 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

6382

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

1350-1355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29567705%20AND%20SRC:MED&resulttype=core&format=json

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 March 2020

cites work

1 reference

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 December 2020

The IFN gamma receptor: a paradigm for cytokine receptor signaling

1 reference

12 December 2020

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

1 reference

12 December 2020

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 December 2020

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

1 reference

12 December 2020

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

12 December 2020

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

12 December 2020

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

12 December 2020

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

12 December 2020

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.

1 reference

12 December 2020

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

12 December 2020

Immune Checkpoint Blockade in Cancer Therapy

1 reference

12 December 2020

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

12 December 2020

Neoantigens in cancer immunotherapy.

1 reference

12 December 2020

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

12 December 2020

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

12 December 2020

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

1 reference

12 December 2020

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

1 reference

12 December 2020

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

12 December 2020

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

1 reference

12 December 2020

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

12 December 2020

Coinhibitory Pathways in Immunotherapy for Cancer

1 reference

12 December 2020

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

1 reference

12 December 2020

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

12 December 2020

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

12 December 2020

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

1 reference

12 December 2020

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

1 reference

12 December 2020

CANCER IMMUNOLOGY. The "cancer immunogram".

1 reference

12 December 2020

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

12 December 2020

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

12 December 2020

The epigenetic landscape of T cell exhaustion.

1 reference

12 December 2020

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

1 reference

12 December 2020

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

1 reference

12 December 2020

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

1 reference

12 December 2020

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

1 reference

12 December 2020

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

1 reference

12 December 2020

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

1 reference

12 December 2020

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

12 December 2020

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

1 reference

12 December 2020

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

1 reference

12 December 2020

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

1 reference

12 December 2020

Identification of essential genes for cancer immunotherapy.

1 reference

12 December 2020

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

1 reference

12 December 2020

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

1 reference

12 December 2020

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

1 reference

12 December 2020

Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

1 reference

12 December 2020

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

1 reference

12 December 2020

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

1 reference

12 December 2020

High response rate to PD-1 blockade in desmoplastic melanomas.

1 reference

12 December 2020

1 reference

12 December 2020